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Abstract The acidity constants of the two-fold proton-
ated acyclic 9-[2-(phosphonomethoxy)ethyl]-8-azaade-
nine, H2(9,8aPMEA)
±, and its 8-isomer, 8-[2-(phos-
phonomethoxy)ethyl]-8-azaadenine, H2(8,8aPMEA)
±,
both abbreviated as H2(PA)
±, as well as the stability
constants of their M(H;PA)+ and M(PA) complexes
with the metal ions M2+=Mg2+, Ca2+, Sr2+, Ba2+,
Mn2+, Co2+, Ni2+, Cu2+, Zn2+ or Cd2+, have been
determined by potentiometric pH titrations in aqueous
solution at I=0.1 M (NaNO3) and 25 C. Application
of previously determined straight-line plots of
log KMMðRPO3Þ versus pK
H
HðRPO3Þ for simple phos-
ph(on)ate ligands, R-PO23 , where R represents a resi-
due without an aﬃnity for metal ions, proves that for
all M(PA) complexes a larger stability is observed than
is expected for a sole phosphonate coordination of the
metal ion. This increased stability is attributed to the
formation of ﬁve-membered chelates involving the
ether oxygen present in the aliphatic residue
(-CH2-O-CH2-PO
2
3 ) of the ligands. The formation
degrees of these chelates were calculated; they vary
between about 13% for Ca(8,8aPMEA) and 71% for
Cu(8,8aPMEA). The adenine residue has no inﬂuence
on complex stability except in the Cu(9,8aPMEA) and
Zn(9,8aPMEA) systems, where an additional stability
increase attributable to the adenine residue is observed
and equilibria between four diﬀerent isomers exist. This
means (1) an open isomer with a sole phosphonate
coordination, M(PA)op, where PA
2=9,8aPMEA2,
(2) an isomer with a ﬁve-membered chelate involving
the ether oxygen, M(PA)cl/O, (3) an isomer which
contains ﬁve- and seven-membered chelates formed by
coordination of the phosphonate group, the ether
oxygen and the N3 site of the adenine residue,
M(PA)cl/O/N3, and ﬁnally (4) a macrochelated isomer
involving N7, M(PA)cl/N7. For Cu(9,8aPMEA) the
formation degrees are 15, 30, 48 and 7% for Cu(PA)op,
Cu(PA)cl/O, Cu(PA)cl/O/N3 and Cu(PA)cl/N7, respectively;
this proves that the macrochelate involving N7 is a
minority species. The situation for the Cu(PMEA) sys-
tem, where PMEA2 represents the parent compound,
i.e. the dianion of 9-[2-(phosphonomethoxy)ethyl]ade-
nine, is quite similar. The relationship between the an-
tiviral activity of acyclic nucleoside phosphonates and
the structures of the various complexes is discussed and
an explanation is oﬀered why 9,8aPMEA is biologically
active but 8,8aPMEA is not.
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Introduction
The idea to use nucleotide analogues as therapeutic agents
has a long tradition [1, 2] and all building blocks of a
nucleotide have been altered and varied over the years
(see, for example, [3] and references therein). Within the
large group of acyclic nucleotide analogues ([4, 5, 6] and
references therein), two series deserve recognition, i.e. the
(S)-3-hydroxy-2-(phosphonomethoxy)propyl (HPMP)
derivatives and the (phosphonomethoxy)ethyl (PME)
derivatives [7, 8]1,2. Representative compounds of these
series are (S)-9-[3-hydroxy-2-(phosphonomethoxy)pro-
pyl]adenine (HPMPA) and 9-[2-(phosphonometh-
oxy)ethyl]adenine (PMEA) [4, 5, 6, 8], both of which are
active against a wide range of viruses, including herpesvi-
ruses, poxviruses [9], hepadnaviruses and retroviruses [4, 5,
6, 10]. This discovery [10] goes back to 1986 and in 2002 one
of these compounds, namely PMEA, now known as Ade-
fovir [4, 5, 6], was approved by the US Food and Drug
Administration (FDA)3 in its oral prodrug form, i.e. its
bis(pivaloyloxymethyl)ester (Adefovir dipivoxil [4, 5, 6]),
for the treatment of hepatitis B patients who suﬀer from the
infection of a DNA virus. For the same treatment, the same
compound but under the name Hepsera was also approved
in March 2003 for ‘‘Community Marketing’’ by the
EuropeanAgency for theEvaluation ofMedicinal Products
(EMEA)4.
The dianion of PMEA, which can be considered as an
analogue of (2¢-deoxy)adenosine 5¢-monophosphate
[(d)AMP2] (Fig. 1 [11, 12, 13]) is converted in the cells
[4, 5, 6] into its diphosphorylated form, PMEApp4,
which is an analogue of (2¢-deoxy)adenosine 5¢-triphos-
phate [(d)ATP4]. PMEApp4 is initially recognized by
nucleic acid polymerases as a substrate and incorporated
in the growing nucleic acid chain, which is then termi-
nated due to the lack of a 3¢-hydroxy group. In the
polymerase reaction, two metal ions are involved [14, 15,
16]: one needs to be coordinated to the b,c-phosphate
units and the other to the a-phosphate group [17, 18] to
promote the transfer of a nucleotidyl residue [19]. The
observation that PMEApp4 is initially a better sub-
strate than the parent dATP4 [20, 21] was rationalized
by the suggestion [19, 22, 23] that the ether oxygen atom
present in PMEA facilitates the M2+/a-phosph(on)ate
coordination by the formation of a ﬁve-membered
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Fig. 1 Chemical structures of adenosine 5¢-monophosphate
(AMP2) and of the dianions of 9-[2-(phosphonometh-
oxy)ethyl]adenine (PMEA2=Adefovir) [4, 5, 6], 9-[2-(phospho-
nomethoxy)ethyl]-8-azaadenine (9,8aPMEA2) and of 8-[2-(phos-
phonomethoxy)ethyl]-8-azaadenine (8,8aPMEA2), together with
the structure of PME-R2, where R is a non-interacting residue,
which represents the metal ion-coordinating properties of the ether-
phosphonate chain occurring in PMEA2, 9,8aPMEA2 and
8,8aPMEA2. A further ligand to be considered in this study is
9-(4-phosphonobutyl)adenine, which is abbreviated as dPMEA2
(=3¢-deoxa-PMEA2) to indicate that its structure corresponds to
that of PMEA2 except that the ether O atom is replaced by a CH2
group. It should be noted that AMP2 is shown in its dominating
anti conformation [11, 12] and that the orientation of PMEA2 in
solution [13] resembles this anti conformation
1For further abbreviations see the legends to Figs. 1 and 2
2Species written without a charge either do not carry one or rep-
resent the species in general (i.e. independent of their protonation
degree); which of the two possibilities applies is always clear from
the context. In formulas like M(H;PA)+, the H+ and PA2 are
separated by a semicolon to facilitate reading, yet they appear
within the same parenthesis to indicate that the proton is at the
ligand without deﬁning its location
3Information regarding US FDA: (2002) Chem Rundschau (CH-
4501 Solothurn, Switzerland) no. 19 (Oct 8), p 68
4Information regarding EMEA as downloaded from the World
Wide Web in December 2003: http://www.emea.eu.int/humandocs/
PDFs/EPAR/hepsera/610202en1.pdf
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chelate ring, as is expressed in a simpliﬁed manner in
equilibrium 1:
In fact, it is well known that this ether oxygen is
crucial for the biological activity of PMEA and that its
replacement by an S atom [24] or a CH2 unit [20] results
in inactive compounds. Similarly, the position of this O
atom within the aliphatic chain is crucial; already the
insertion of one additional CH2 unit deprives the
resulting analogue of any useful antiviral activity [21,
25]; indeed, the six-membered chelate-ring analogue of
equilibrium 1 is considerably less stable with metal ions
like Mg2+ and Zn2+ or does even not form at all
(Ferna´ndez-Botello A, Griesser R, Holy´ A, Moreno V,
Sigel H, to be published).
With the mentioned observations in mind and with the
aim to delineate further the structure–function relation-
ship, we studied the metal ion-binding properties of the
PMEA analogue 9-[2-(phosphonomethoxy)ethyl]-8-aza-
adenine (9,8aPMEA) and its isomer 8-[2-(phosphono-
methoxy)ethyl]-8-azaadenine (8,8aPMEA) (see Fig. 1).
This nucleobase modiﬁcation, i.e. the replacement of
(C8)H by N [26], was initiated by the more than 50-years-
old discovery of the antibacterial [27] and antitumor [28]
properties of 8-azaguanine, which has led to a continued
interest in 8-azapurines and related nucleosides [29, 30,
31, 32]. Interestingly, the present study reveals that
the metal ion-binding properties of 9,8aPMEA2 are
very similar to those of PMEA2 whereas the ones of
8,8aPMEA2 diﬀer, and these diﬀerences are also
reﬂected in their biological activity [26, 33].
A further point to be emphasized is that the presence
of the ether oxygen atom (Fig. 1) in all three nucleotide
analogues, i.e. PMEA2 [22, 23, 34, 35, 36],
8,8aPMEA2 and 9,8aPMEA2, gives rise to the already
mentioned equilibrium 1 with all the metal ion com-
plexes studied. This property distinguishes the com-
plexes of these analogues from those of their parent
nucleotide AMP2, which does not have this possibility
and therefore forms either simply complexes with the
phosphate residue or, as in the case of several divalent
3d metal ions, in addition macrochelates involving N7
[37, 38, 39, 40]; this situation is indicated in a simpliﬁed
way in the intramolecular equilibrium 2:
As we shall see below, for the M(8,8aPMEA) complexes,
equilibrium 1 is of relevance, whereas for some of the
M(9,8aPMEA) species the situation is considerably
more complicated [41] and both equilibria 1 and 2 are to
some extent of relevance.
Materials and methods
Materials
Twofold protonated 9-[2-(phosphonometh-
oxy)ethyl]-8-azaadenine, i.e. H2(9,8aPMEA)
±, and its
8-isomer, 8-[2-(phosphonomethoxy)ethyl]-8-azaadenine,
H2(8,8aPMEA)
±, were synthesized by alkylation of 8-
azaadenine with a synthon carrying the structural con-
stituents of the required side chain [26]. For the present
study, compounds from the same lots used previously [41,
42] were applied. The aqueous solutions of the ligands
were freshly prepared daily just before the experiments by
dissolving the substance in deionized, ultrapure (MILLI-
Q185 PLUS; from Millipore, Molsheim, France) CO2-
free water, adjusted to pH about 8.5 by adding 2 equiv of
0.1 NaOH.
The disodium salt of 1,2-diaminoethane-N,N,N¢,N¢-
tetraacetic acid (Na2H2EDTA), potassium hydrogen
phthalate, HNO3, NaOH (Titrisol), and the nitrate salts
of Na+, Mg2+, Ca2+, Sr2+, Ba2+, Mn2+, Co2+, Ni2+,
Cu2+, Zn2+ and Cd2+ (all pro analysi) were from
Merck (Darmstadt, Germany). All solutions for the
potentiometric pH titrations were prepared with the
mentioned ultrapure CO2-free water. The buﬀer solu-
tions (pH 4.00, 7.00, 9.00, based on the NBS scale; now
NIST) for calibration were from Metrohm (Herisau,
Switzerland).
The exact concentrations of the stock solutions of
the divalent metal ions were determined by potentio-
metric pH titrations via their EDTA complexes by
measuring the equivalents of protons liberated from
H(EDTA)2 upon complex formation with M2+. The
exact concentration of the ligand solutions was newly
determined for each experiment by evaluation of the
corresponding titration pairs, i.e. the diﬀerences in
NaOH consumption between solutions with and
without ligand (see below).
Potentiometric pH titrations
The pH titration curves for the determination of the
equilibrium constants in aqueous solution were recorded
with a Metrohm E536 potentiograph connected to a
Metrohm E655 dosimat and a Metrohm 6.0222.100
combined macro glass electrode. The pH calibration of
the instrument was carried out with the mentioned buﬀer
solutions of pH 4.00, 7.00 and 9.00. The titer of theNaOH
used was determined with potassium hydrogen phthalate.
The direct pH meter readings were used in the
calculations of the acidity constants, i.e. these constants
determined at I=0.1 M (NaNO3) and 25 C are
so-called practical, mixed or Brønsted constants [43].
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They may be converted into the corresponding con-
centration constants by subtracting 0.02 from the listed
pKa values; this conversion term contains both the
junction potential of the glass electrode and the
hydrogen ion activity [43, 44]. It should be emphasized
that the ionic product of water (Kw) and the mentioned
conversion term do not enter into our calculation pro-
cedure because we always evaluate the diﬀerences in
NaOH consumption between a pair of solutions, i.e. with
and without ligand. The stability constants determined
are concentration constants.
All equilibrium constants were calculated by curve-
ﬁtting procedures in the way and with the equipment
described previously [45, 46].
Determination of equilibrium constants
The acidity constants KHH2ð9;8aPMEAÞ (Eq. 4b) and
KHHð9;8aPMEAÞ (Eq. 5b) of H2(9,8aPMEA)
±, where one
proton is at N1 of the adenine moiety and the other at
the phosphonate group, were determined recently
[41] and these results were also conﬁrmed now (25 C;
I=0.1 M, NaNO3). The stability constants
KMMðH;9;8aPMEAÞ (Eq. 6b) and K
M
Mð9;8aPMEAÞ (Eq. 7b) of the
M(H;9,8aPMEA)+ and M(9,8aPMEA) complexes,
respectively, were determined under the same conditions
as the acidity constants [41]. This means that 30 mL of
aqueous 0.83 mM HNO3 were titrated in the presence
and absence of 0.4 mM deprotonated ligand under N2
with 1 mL of 0.03 M NaOH (the diﬀerences in NaOH
consumption between such a pair of titrations were used
for the calculations), but NaNO3 was partly or fully
replaced by M(NO3)2 (25 C; I=0.1 M). The M2+/li-
gand ratios were 83:1 (Mg2+, Ca2+, Sr2+, Ba2+,
Mn2+), 75:1 (Mg2+), 73.4:1 (Mn2+), 55.6:1 (Mg2+,
Ca2+), 52:1 (Ca2+), 50:1 (Mn2+, Co2+), 49:1 (Co2+),
41.7:1 (Sr2+, Ba2+), 28:1 (Cd2+), 25:1 (Co2+), 14:1
(Cd2+), 13:1 (Cd2+), 11:1 (Cu2+) and 5.5:1 (Cu2+).
The acidity constants KHH2ð8;8aPMEAÞ (Eq. 4b) and
KHHð8;8aPMEAÞ (Eq. 5b) of H2(8,8aPMEA)
± were deter-
mined by titrating 30 mL of aqueous 1.27 mM HNO3 in
the presence and absence of 0.4 mM deprotonated
ligand with 1.3 mL of 0.03 M NaOH (25 C; I=0.1 M,
NaNO3). The diﬀerences in NaOH consumption
between such a pair of titrations were used in the cal-
culations. The pH range from 3.6 to 8.0 was evaluated,
which corresponds to an initial formation degree of 48%
for H2(8,8aPMEA)
± and to a ﬁnal deprotonation
degree of 94% for 8,8aPMEA2. The results for the
two acidity constants are the averages of 13 pairs of
independent titrations.
The stability constants KMMðH;8;8aPMEAÞ (Eq. 6b) and
KMMð8;8aPMEAÞ (Eq. 7b) of the M(H;8,8aPMEA)
+ and
M(8,8aPMEA) complexes were determined under the
same conditions as the acidity constants, but NaNO3
was partly or fully replaced by M(NO3)2 (25 C;
I=0.1 M). The M2+/ligand ratios were 83:1 (Mg2+,
Ca2+, Sr2+, Ba2+, Mn2+), 55.6:1 (Mg2+, Ca2+), 50:1
(Co2+, Ni2+), 41.7:1 (Sr2+, Ba2+, Mn2+), 28:1 (Zn2+,
Cd2+), 25:1 (Co2+, Ni2+), 14:1 (Cd2+), 11:1 (Cu2+,
Zn2+) and 5.5:1 (Cu2+).
The stability constants were calculated by considering
H+, H2(PA)
±, H(PA), PA2, M2+, M(H;PA)+ and
M(PA), where PA2=9,8aPMEA or 8,8aPMEA2.
However, the formation of the monoprotonated
M(H;PA)+ complexes was usually rather small and
therefore values for the corresponding constants had to
be estimated. These estimations were based on the
relationship between complex stability and ligand donor
group basicity [47], i.e. log Kstability versus pKa results in
a straight line for families of closely related ligands and
their complexes. This line is deﬁned by the equation
y=mx+b, where x represents the pKa value, y the log-
arithm of the calculated stability constant of the corre-
sponding M2+–ligand complex, and m the slope of the
straight line, b being the intercept with the y-axis. For
the slope we used the average of the straight-line equa-
tions deﬁned previously for benzimidazole- [48], imid-
azole- [49] and pyridine-type [50] ligands and their
corresponding complexes. The stability constants for
M(H;PA)+ species were provided by two structurally
related adenine derivatives, i.e. 9-[2-(phosphono-
methoxy)ethyl]adenine (PMEA; pKHH2ðPMEAÞ=4.16 [51])
and 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine
(PMEDAP; pKHH2ðPMEDAPÞ=4.82 [45]); the correspond-
ing stability constant values have been tabulated [45, 51].
Since the pKHH2ðPAÞ values are known, log stability con-
stants for M(H;PA)+ complexes could be calculated
from the PMEA as well as from the PMEDAP data; the
average of these two results obtained for each metal ion
was then used in the ﬁnal calculations.
For the 9,8aPMEA systems the experimental data
were collected every 0.1 pH unit, beginning at about
1.5% of complex formation for M(H;9,8aPMEA)+ to a
neutralization degree of about 90% with respect to the
species H(9,8aPMEA) or until the beginning of
the hydrolysis of M(aq)2+, which was evident from the
titrations without ligand. The maximal formation degree
for the M(H;9,8aPMEA)+ and M(9,8aPMEA) species
varies between 1.6–8.7% and 25.8–89.9%, respectively,
depending on the metal ion considered. For the
corresponding complexes with Ni2+, Cu2+ and Zn2+,
reference [41] should be consulted.
For the 8,8aPMEA systems the experimental data
were also collected every 0.1 pH unit from a formation
degree of about 0.9% for the M(H;8,8aPMEA)+ com-
plex to a neutralization degree of about 90% with regard
to the H(8,8aPMEA) species or until the beginning of
the hydrolysis of M(aq)2+, which was again evident
from the titrations in the absence of ligand. The maximal
formation degree for the M(H;8,8aPMEA)+ and
M(8,8aPMEA) complexes varied between 1.5–12.4%
and 22.8–89.5%, respectively.
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It needs to be emphasized that the results showed no
dependence on the excess of metal ion concentration
employed in the various experiments. The ﬁnal results
for the stability constants of the complexes listed below
are the averages of at least ﬁve independent titrations for
each system.
Results and discussion
It is well known that nucleobases and their derivatives
can undergo self-association via p stacking [11, 52, 53].
Therefore, the experimental conditions for the determi-
nation of the equilibrium constants by potentiometric
pH titrations (25 C; I=0.1 M, NaNO3) were selected
such that the results summarized below refer to mono-
meric species. This is ascertained with ligand concen-
trations of 0.4 mM, as has been shown previously for
PMEA [51].
Acidity constants of H3(8,8aPMEA)
+
and H3(9,8aPMEA)
+
The ligands 8,8aPMEA2 and 9,8aPMEA2, abbrevi-
ated as PA2, may accept three protons, two at the
phosphonate group and one at the N1 site of the adenine
residue [13] (see Fig. 1). Further protonations of the
adenine residue are possible at N7 and N3, but these
protons are released at pKa<0 [54, 55], and therefore
they are not considered in this study. At pH>0 the
strongest acid that can be derived in aqueous solution
from PA2 is H3(PA)
+. Hence, the following three
deprotonation reactions need to be considered:
H3ðPAÞþ  H2ðPAÞ þHþ (3a)
KHH3ðPAÞ ¼ [H2(PA)][Hþ]/[H3(PA)þ] (3b)
H2(PA)
  H(PA) þHþ (4a)
KHH2ðPAÞ ¼ [H(PA)][Hþ]/[H2(PA)] (4b)
HðPAÞPA2 þHþ (5a)
KHHðPAÞ ¼ ½PA2½Hþ=½HðPAÞ (5b)
However, the ﬁrst proton according to equilibrium 3a is
released from the P(O)(OH)2 group of H3(PA)
+, and
from the results obtained previously for H3(PMEA)
+ it
is known that pKHH3ðPMEAÞ=1.22±0.13 [13]. The same
value may be surmised for the corresponding acidity
constant of H3(8,8aPMEA)
+ and H3(9,8aPMEA)
+.
Hence, for the present study, for which all potentio-
metric pH titrations were carried out in the pH range
above 3 (see ‘‘Determination of equilibrium constants’’
and [41, 42]), equilibrium 3a is actually also not of
relevance. Here, only the release of the protons from
H2(PA)
± need to be considered, i.e. the ﬁrst one from
the (N1)H+ site (Eq. 4a) and the next one from the
P(O)2(OH)
 group (Eq. 5a). The corresponding acidity
constants are listed in Table 1, together with some
related data [56, 57, 58, 59, 60, 61, 62].
The data in Table 1 oﬀer comparisons for many
conclusions; a few are given below:
1. Comparison of entries 1 and 2 with entry 3 conﬁrms
the conclusion indicated above that the ﬁrst proton in
H2(9,8aPMEA)
± is released from the (N1)H+ site of
the 8-azaadenine residue [56] and the second one
from the monoprotonated phosphonate group.
2. Similarly, the combination of the values from entries
6 and 2 gives those of entry 5 and conﬁrms the
corresponding site attributions of the protons in
H2(PMEA)
± [13, 51].
3. Comparison of entries 1 and 3 with 5 and 6 demon-
strates that replacement of (C8)H by N acidiﬁes the
(N1)H+ site by about 1.4 p K units; however, this
substitution at position 8 of the purine ring has no
remarkable eﬀect on the basicity of the phosphonate
group.
4. Similarly, the phosphonate group remains largely
unaﬀected if the aliphatic side chain with the ether
oxygen atom is moved from position 9 to 8 of the
purine ring but the (N1)H+ site is now acidiﬁed only
by Dp Ka=0.6, as a comparison of entries 4 and 5
demonstrates.
Table 1 Negative logarithms of the acidity constants of H2(PA)
±,
where PA2=8,8aPMEA2 or 9,8aPMEA2 (Eqs. 4a,b and 5a,b),
as determined by potentiometric pH titrations in aqueous solution
at 25 C and I=0.1 M (NaNO3), together with the corresponding
values of some related systemsa,b
No Protonated speciesc pKHH2ðPAÞ pK
H
HðPAÞ Ref
(N1)H+ P(O)2(OH)

1 H(9Me8azaAde)+ 2.70d [56]
2 H(PME-R) 6.99±0.04e –e
3 H2(9,8aPMEA)
± 2.73±0.02 6.85±0.02 –f,g
4 H2(8,8aPMEA)
± 3.56±0.02 6.79±0.01 –f
5 H2(PMEA)
± 4.16±0.02 6.90±0.01 [13, 51]
6 H(9MeAde)+ 4.10±0.01 [54, 55, 59]
7 H2(dPMEA)
± 4.17±0.02 7.69±0.01 [46]
8 CH3P(O)2(OH)
 7.51±0.01 [60, 61]
9 H2(AMP)
± 3.84±0.02 6.21±0.01 [37, 62]
aThe error limits given are three times the standard error of the
mean value or the sum of the probable systematic errors, whichever
is larger
bSo-called practical, mixed or Brønsted constants are listed [43]
c9Me8azaAde=9-methyl-8-azaadenine; 9MeAde=9-methylade-
nine
dValue based on 1H NMR shift experiments (I=0.5 M, KNO3)
[56]; a very similar result was obtained in an early spectrophoto-
metric study [57]
eAverage of the values due to (phosphonomethoxy)ethane (PME2;
R=H) [51] and 1-[2-(phosphonomethoxy)ethyl]cytosine (PMEC2;
R=cytosine residue) [58]
fThis study
gThe values given in [41] are now also conﬁrmed
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5. On the other hand, replacement of the ether oxygen
by a methylene group in the alkyl chain has no eﬀect
on the basicity of N1 (see entries 5 and 7), but it
increases the basicity of the phosphonate group by
about 0.8 pK units. This conclusion is further con-
ﬁrmed by comparing entries 2–5 with 7 and 8.
6. Of further interest is a comparison of the values for
H2(AMP)
± (entry 9) with some other data. It is
evident that the (N1)H+ site in H2(AMP)
± is only a
bit more acidic than the same site in H(9MeAde)+ or
H2(PMEA)
± (entries 5, 6). This means that the
replacement of the ribosyl residue in AMP by the
ether oxygen-containing aliphatic chain has little ef-
fect on the aromatic ring system. However, the
phosphate residue, -OP(O)2(OH)
, of H(AMP) is
by about 0.7 p K units more acidic than the phos-
phonate group, -P(O)2(OH)
 (entries 5, 9). This
means that the phosphate group is practically com-
pletely deprotonated at physiological pH (ca. 7.5),
whereas the phosphonate group still carries a proton
to some extent (about 20%) [13].
Stability constants of M(H;PA)+ and M(PA) complexes
for PA2=8,8aPMEA2 and 9,8aPMEA2
The experimental data of the potentiometric pH titra-
tions of all the M2+/PA systems can be described
completely by equilibria 4a, 5a, 6a and 7a,
M2þ þHðPAÞMðH;PAÞþ (6a)
KMMðH;PAÞ ¼ [M(H;PA)þ]/([M2þ][H(PA)]) (6b)
M2þ þ PA2M(PA) (7a)
KMMðPAÞ ¼ [M(PA)]/([M2þ][PA2]) (7b)
if the evaluation is not carried into the pH range where
hydroxo complexes form. The acidity constant of equi-
librium 8a may be calculated with Eq. 9:
M(H;PA)þM(PA)þHþ (8a)
KHMðH;PAÞ ¼ [M(PA)][Hþ]/[M(H;PA)þ] (8b)
pKHMðH;PAÞ ¼pKHHðPAÞ þ logKMMðH;PAÞ  logKMMðPAÞ (9Þ
The results are listed in Table 2; the stability con-
stants given for the M(H;PA)+ complexes are only
estimates since the formation degree of these species
was low (see ‘‘Determination of equilibrium con-
stants’’). The stability constants of the M(PA) com-
plexes show the usual trends. For the alkaline earth
ions the stability decreases with increasing ionic radii,
indicating that metal ion binding at the phosphonate
group is (at least) in part inner-sphere. For the
divalent 3d metal ions the long-standing experience
[51, 63] is conﬁrmed that the stabilities of phosph(o-
n)ate–metal ion complexes often do not strictly follow
[34, 38, 39, 45, 62, 64, 65, 66] the Irving–Williams
sequence [67], an observation in accord with the fact
that in ligands of this kind the phosph(on)ate group is
always the main binding site [35, 36, 38, 39, 62, 65] in
M(PA) complexes (see the next section and Fig. 2
below).
As far as the M(H;PA)+ complexes are concerned,
it is evident that the evaluation of potentiometric pH
titration data only allows the determination, or in the
present case estimation, of their stability constants.
Further information is required to detect the binding
sites of the proton and the metal ion. At ﬁrst, one may
ask where the proton is located because binding of a
metal ion to a protonated ligand commonly leads to
an acidiﬁcation of the ligand-bound proton [68, 69].
Indeed, the acidity constants of the M(H;PA)+ com-
plexes given in column 5 of Table 2 are about 1.3–
3 pK units smaller than pKHHðPAÞ (Table 1), but about
0.9–2.8 log units larger than pKHH2ðPAÞ: This comparison
shows that the proton in M(H;PA)+ is clearly located
at the phosphonate group; hence, one may tentatively
Table 2 Logarithms of the stability constants of the M(H;PA)±
(Eq. 6a,b) and M(PA) complexes (Eq. 7a,b), where PA2=
8,8aPMEA2 or 9,8aPMEA2, as determined by potentiometric
pH titrations, together with the negative logarithms of the acidity
constants of the monoprotonated M (H;PA)+complexes (Eqs. 8a,b
and 9) (aqueous solution; 25 C; I=0.1 M, NaNO3)a,b
PA2 M2+ log KMMðH;PAÞ
c log KMMðPAÞ pK
H
MðH;PAÞ
8,8aPMEA2 Mg2+ 0.2 1.83±0.07 5.16±0.26
Ca2+ 0.15 1.59±0.03 5.35±0.25
Sr2+ 0.1 1.37±0.03 5.52±0.25
Ba2+ 0.0 1.34±0.04 5.45±0.25
Mn2+ 0.3 2.45±0.02 4.64±0.25
Co2+ 0.55 2.28±0.04 5.06±0.25
Ni2+ 0.9 2.27±0.03 5.42±0.25
Cu2+ 1.3 3.68±0.06 4.41±0.26
Zn2+ 1.0 2.64±0.09 5.15±0.27
Cd2+ 1.0 2.89±0.08 4.90±0.26
9,8aPMEA2 Mg2+ 0.2 1.84±0.04 5.21±0.25
Ca2+ 0.15 1.62±0.08 5.38±0.26
Sr2+ 0.1 1.41±0.04 5.54±0.25
Ba2+ 0.0 1.38±0.05 5.47±0.26
Mn2+ 0.15 2.49±0.04 4.51±0.25
Co2+ 0.4 2.33±0.04 4.92±0.25
Ni2+ 0.7 2.25±0.08 5.30±0.26
Cu2+ 0.95 3.98±0.04 3.82±0.25
Zn2+ 0.8 2.82±0.09 4.83±0.27
Cd2+ 0.75 2.93±0.06 4.67±0.26
aFor the error limits, see footnote (a) of Table 1. The error limits
(3r) of the derived data, in the present case for column 5, were
calculated according to the error propagation after Gauss
bThe values for the Ni2+, Cu2+ and Zn2+ systems of 9,8aPMEA
are taken from [41]. The titrations with Zn2+ were hampered by
precipitation, i.e. the pH range suitable for the evaluation of the
stability constants was restricted [41]
cThe stability constants listed for the M(H;PA)+ complexes as well
as the error limits (±0.25 log units) are estimates
966
assume that the metal ion is bound preferentially to
the nucleobase, since a monoprotonated phosphonate
group is only a weak binding site. Indeed, this suggestion
agrees with evidence obtained previously for other related
M(H;PA)+ species [35, 36, 51]. It is further supported by
the observation that the estimated stabilities of the
M(H;PA)+ complexes follow the Irving–Williams se-
quence [67], as is typical for metal ion binding to nitrogen
donor sites [63], the preferred site most likely being N7 [70,
71].
Evidence for an enhanced stability of the M(8,8aPMEA)
and M(9,8aPMEA) complexes
The 8,8aPMEA2 and 9,8aPMEA2 ligands oﬀer four
potential binding sites for the coordination of metal
ions: the two-fold negatively charged phosphonate
group, the ether oxygen of the -CH2CH2-O-CH2-PO
2
3
chain (see Fig. 1) and the adenine residue with its N7
and N3 sites; the N1 is not accessible by a phosphonate-
bound metal ion [34, 51]. The phosphonate group is
clearly the primary binding site for all metal ions con-
sidered in this study and therefore any participation in
metal ion binding of one (or more) of the other potential
sites has to be reﬂected in a relative stability increase
[47]. Hence, it is necessary to deﬁne the stability of a
pure PO23 =M
2þ interaction. This can be done by
applying the previously deﬁned [34, 65, 72] straight-line
correlations which are based on log KM
MðRPO3)
versus
pKH
HðRPO3)
plots for simple phosphate monoesters [73]
and phosphonates [51]; these ligands are abbreviated as
R-PO23 , where R represents a non-coordinating residue.
The parameters for the corresponding straight-line
equations, which are deﬁned by Eq. 10,
log KM
MðRPO3)
¼ m pKH
HðRPO3)
þ b ð10Þ
have been tabulated [34, 51, 65, 72], i.e. the slopes m and
the intercepts b with the y axis. Hence, with a known pKa
value for the deprotonation of a P(O)2(OH)
 group an
expected stability constant can be calculated for any
phosph(on)ate–metal ion complex.
Corresponding plots of log KM
MðRPO3)
versus
pKH
HðRPO3)
according to Eq. 10 are shown in Fig. 2
for 1:1 complexes of Ba2+, Mg2+, Zn2+ and Cu2+, as
examples, with the data points (open circles) of the
eight simple ligand systems used [51, 73] for the
determination of the straight reference lines [51].
The data points for the M2+ complexes of PMEA2
and its 8-aza analogues are for all four metal ion
systems clearly above the reference lines, thus proving
an increased stability for all 12 complexes considered
though the stability enhancements for the Mg2+ and
Ba2+ complexes are relatively small.
Furthermore, it is evident that the stability increase
for the Mg2+ and Ba2+ complexes is within the error
limits identical for all three ligands and this indicates
that here equilibrium 1 is of relevance, since the
aﬃnity of the alkali earth metal ions toward N sites is
small [63]. This observation contrasts with that made
for the Cu2+ and Zn2+ complexes since their stability
enhancement evidently diﬀers for 8,8aPMEA2 and
Fig. 2 Evidence for an enhanced stability of several M(9,8aPMEA)
(crossed diamonds), M(8,8aPMEA) (solid diamonds) and M(PMEA)
(crossed circles) complexes, based on the relationship between
log KM
MðRPO3)
and pKH
HðRPO3)
for M(R-PO3) complexes of some
simple phosphate monoester and phosphonate ligands (R-PO23 )
(open circles): 4-nitrophenyl phosphate (NPhP2), phenyl phos-
phate (PhP2), uridine 5¢-monophosphate (UMP2), D-ribose
5-monophosphate (RibMP2), thymidine [=1-(2¢-deoxy-b-D-ribo-
furanosyl)thymine] 5¢-monophosphate (dTMP2), n-butyl phos-
phate (BuP2), methanephosphonate (MeP2) and
ethanephosphonate (EtP2) (from left to right). The least-squares
lines (Eq. 10) are drawn through the corresponding eight data sets
(open circles) taken from [73] for the phosphate monoesters and
from [51] for the phosphonates. The points due to the equilibrium
constants for the M2+/9,8aPMEA (crossed diamonds) and M2+/
8,8aPMEA (solid diamonds) systems are based on the values listed
in Tables 1 and 2; those for the M2+/PMEA systems (crossed
circles) are from [51]. The vertical broken lines emphasize the
stability diﬀerences from the reference lines; they equal log
DM/9,8aPMEA and log DM/8,8aPMEA, as deﬁned in Eqs. 11a and
11b, for the M(9,8aPMEA) and M(8,8aPMEA) complexes,
respectively. All the plotted equilibrium constants refer to aqueous
solutions at 25 C and I=0.1 M (NaNO3)
967
9,8aPMEA2, indicating that here at least to some
extent the adenine residue is (also) involved in metal
ion binding. This is conﬁrmed by the data points for
the Cu2+ complexes of PMEA2 and 9,8aPMEA2,
which indicate the same stability enhancement, and for
Cu(PMEA) the involvement in metal ion binding of
the adenine residue has been proven. The apparent
diﬀerence for the corresponding Zn2+ complexes
should not be interpreted, since the stability constant
for Zn(PMEA) could not be measured due to pre-
cipitation [51]; it is an estimate only [22, 23] and, in
fact, the corresponding stability constants are within
their (large) error limits identical (see below).
Stability enhancements like those seen in Fig. 2 can
be quantiﬁed by the diﬀerences between the experimen-
tally (exptl) measured stability constants and those cal-
culated (calcd) according to Eq. 10; this diﬀerence is
deﬁned in Eq. 11a,b:
logDM=PA ¼ logKMMðPAÞexptl  logKMMðPAÞcalcd (11a)
¼ log KMMðPAÞ  log KMMðPAÞop ð¼ log DÞ
(11b)
where the expressions log KMMðPAÞcalcd and log K
M
MðPAÞop
are synonymous because the calculated value equals
the stability constant of the ‘‘open’’ isomer, M(PA)op
(see, for example, equilibria 1 and 2), in which only a
PO23 =M
2þ interaction occurs. In columns 3–5 of
Table 3 the values for the three terms of Eq. 11a,b are
listed. All log DM/PA values being positive proves that
at least one further binding site, next to the phos-
phonate group, must be involved in all these M(PA)
complexes.
Evidence for an ether oxygen interaction in the M(PA)
complexes and quantiﬁcation of the corresponding intra-
molecular equilibrium
It is obvious that the vertical distance from the marked
data points in Fig. 2 for the M(PA) complexes to their
reference lines reﬂects the ‘‘intensity’’ of the partici-
pation of any other binding site, next to the phos-
phonate group, in metal ion binding and that this
‘‘intensity’’ is quantiﬁed by Eqs. 11a,b. To learn which
of the above-mentioned additional binding sites (see
also Fig. 1) is responsible for the observed stability
enhancements, we have listed in column 2 of Table 4
the log DM/PME-R values (according to Eqs. 11a,b)
which are solely attributable to the formation of ﬁve-
membered chelates as seen in equilibrium 1 because the
ligand PME-R2 does not oﬀer any other binding site
except the ether oxygen, aside from the phosphonate
group itself (see Fig. 1). The corresponding data
log DM/8,8aPMEA and log DM/9,8aPMEA for the
M(8,8aPMEA) and M(9,8aPMEA) complexes
[=M(PA)] are given in columns 3 and 4 of Table 4,
respectively, and a comparison with those in column 2
is best done by calculating the diﬀerences according to
Eq. 12:
D log DM=PA=PMER ¼ log DM=PA  log DM=PMER
ð12Þ
The corresponding results are listed in columns 6
and 7 for 8,8aPMEA2 and 9,8aPMEA2, respectively.
It is obvious that all the values in column 6 are zero
within the error limits, meaning that the stability
enhancements log DM/8,8aPMEA correspond to those of
log DM/PME-R and that therefore equilibrium 1 operates
in all the M(8,8aPMEA) systems and that only a
M2+–ether oxygen interaction is responsible for the
increased complex stability. Exactly the same is true
for the M(9,8aPMEA) systems, with two exceptions: in
Cu(9,8aPMEA) and Zn(9,8aPMEA) a further interac-
tion next to the one with the ether oxygen must occur,
as is evident from the results listed in column 7.
Since it has been shown previously [41, 46] that in
the Cu(PMEA) species not only equilibrium 1 with the
ether oxygen interaction operates but that also the
adenine residue is involved, mainly via N3 and to a
small extent also via N7 [46], we have summarized the
log DM/PMEA values in column 5 of Table 4 and
the diﬀerences according to Eq. 12 in column 8 at the
Table 3 Stability constant comparisons for the M(PA) complexes,
where PA2=8,8aPMEA2 or 9,8aPMEA2, according to
Eq. 11a,b; that is, between the experimentally measured (exptl) and
the calculated (calcd) log stability constants, the latter being based
on the reference-line equations (Eq. 10) [34, 51, 72] and the pKHHðPAÞ
values (Table 1) of the monoprotonated H(PA) species (aqueous
solution; 25 C; I=0.1 M, NaNO3)a
PA2 M2+ log KMMðPAÞ log DM/PA
exptlb calcd
8,8aPMEA2 Mg2+ 1.83±0.07 1.68±0.03 0.15±0.08
Ca2+ 1.59±0.03 1.53±0.05 0.06±0.06
Sr2+ 1.37±0.03 1.29±0.04 0.08±0.05
Ba2+ 1.34±0.04 1.21±0.04 0.13±0.06
Mn2+ 2.45±0.02 2.30±0.05 0.15±0.05
Co2+ 2.28±0.04 2.07±0.06 0.21±0.07
Ni2+ 2.27±0.03 2.09±0.05 0.18±0.06
Cu2+ 3.68±0.06 3.14±0.06 0.54±0.08
Zn2+ 2.64±0.09 2.33±0.06 0.31±0.11
Cd2+ 2.89±0.08 2.63±0.05 0.26±0.09
9,8aPMEA2 Mg2+ 1.84±0.04 1.70±0.03 0.14±0.05
Ca2+ 1.62±0.08 1.53±0.05 0.09±0.09
Sr2+ 1.41±0.04 1.29±0.04 0.12±0.06
Ba2+ 1.38±0.05 1.22±0.04 0.16±0.06
Mn2+ 2.49±0.04 2.31±0.05 0.18±0.06
Co2+ 2.33±0.04 2.08±0.06 0.25±0.07
Ni2+ 2.25±0.08 2.10±0.05 0.15±0.09
Cu2+ 3.98±0.04 3.17±0.06 0.81±0.07
Zn2+ 2.82±0.09 2.35±0.06 0.47±0.11
Cd2+ 2.93±0.06 2.65±0.05 0.28±0.08
aFor the error limits, see footnote (a) of Table 2
bFrom column 4 of Table 2
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right. Indeed, all the D log DM/PMEA/PME-R values are
again zero within their error limits, pointing again to
the importance of equilibrium 1, but there are also two
exceptions, i.e. the Ni2+ and Cu2+ systems. In fact,
the D log DCu/PMEA/PME-R value is identical with the
one observed for D log DCu/9,8aPMEA/PME-R; the mean-
ing of this result will be discussed further below in the
section ‘‘Cu(9,8aPMEA) and related systems. A four
isomer problem’’.
For the present we shall concentrate on those
18 M(PA) systems for which D log DM/PA/PME-R is
zero within the error limits (see Table 4, columns 6 and
7) and for which the intramolecular equilibrium 1
operates.
The dimensionless intramolecular equilibrium con-
stant, KI/O, is deﬁned by Eq. 13,
KI=O ¼ [M(PA)cl=O]/[M(PA)op] ð13Þ
and values for KI/O can be calculated following known
procedures [47, 51, 62, 65, 72], i.e. via Eq. 14:
KI=O ¼ 10log D  1 ð14Þ
Knowledge of KI/O then allows us, according to
Eq. 15,
% M(PA)cl=O ¼ 100 KI=O/(1þ KI=O) ð15Þ
to obtain the percentage of the closed isomers, M(PA)cl/O,
present in equilibrium 1, i.e. their formation degree. The
corresponding results for the M(8,8aPMEA) and
M(9,8aPMEA) complexes are summarized in Table 5,
where the values for the 9,8aPMEA2 systems with
Cu2+ and Zn2+ are given in parentheses for the reasons
outlined above.
It is remarkable to observe that for a given metal ion
the formation degree of the ﬁve-membered chelate
involving the ether oxygen according to equilibrium 1 is,
within the error limits, identical for the complexes with
both ligands, i.e. 8,8aPMEA2 and 9,8aPMEA2. This
means that the 8-azaadenine residue has no signiﬁcant
inﬂuence on the position of equilibrium 1 and that in all
the complexes formed with Mg2+, Ca2+, Sr2+, Ba2+,
Mn2+, Co2+, Ni2+ and Cd2+ these two ligands simply
Table 4 Comparison of the stability enhancements according to Eq. 11a,b as observed for the M(8,8aPMEA) and M(9,8aPMEA)
complexes (Table 3, column 5), with the corresponding values determined earlier for the related M(PME-R) [58] and M(PMEA) com-
plexes [22, 23, 51] (aqueous solution; 25 C; I=0.1 M, NaNO3)a,b
M2+ log
DM/PME-R
log
DM/8,8aPMEA
log
DM/9,8aPMEA
log
DM/PMEA
D log
DM/8,8aPMEA/PME-R
D log
DM/9,8aPMEA/PME-R
D log
DM/PMEA/PME-R
Mg2+ 0.16±0.04 0.15±0.08 0.14±0.05 0.16±0.05 0.01±0.09 0.02±0.06 0.00±0.06
Ca2+ 0.12±0.05 0.06±0.06 0.09±0.09 0.11±0.07 0.06±0.08 0.03±0.10 0.01±0.09
Sr2+ 0.09±0.05 0.08±0.05 0.12±0.06 0.07±0.05 0.01±0.07 0.03±0.08 0.02±0.07
Ba2+ 0.11±0.05 0.13±0.06 0.16±0.06 0.08±0.06 0.02±0.08 0.05±0.08 0.03±0.08
Mn2+ 0.19±0.06 0.15±0.05 0.18±0.06 0.21±0.08 0.04±0.08 0.01±0.08 0.02±0.10
Co2+ 0.20±0.06 0.21±0.07 0.25±0.07 0.28±0.07 0.01±0.09 0.05±0.09 0.08±0.09
Ni2+ 0.14±0.07 0.18±0.06 0.15±0.09 0.30±0,07 0.04±0.09 0.01±0.11 0.16±0.10
Cu2+ 0.48±0.07 0.54±0.08 0.81±0.07 0.77±0.07 0.06±0.11 0.33±0.10 0.29±0.10
Zn2+ 0.29±0.07 0.31±0.11 0.47±0.11 0.30±0.10c 0.02±0.13 0.18±0.13 0.01±0.12c
Cd2+ 0.30±0.05 0.26±0.09 0.28±0.08 0.33±0.06 0.04±0.10 0.02±0.09 0.03±0.08
aFor the error limits, see footnote (a) of Table 2
bThe values in columns 6, 7 and 8 for D log DM/8,8aPMEA/PME-R,
D log DM/9,8aPMEA/PME-R and D log DM/PMEA/PME-R (Eq. 11a,b)
result from the comparison between the stability enhancements
observed for the M(8,8aPME-R), M(9,8aPME-R) or M(PMEA)
complexes and the ones for the M(PME-R) complexes, respectively
cThis value is an estimate since the stability constant for the
Zn(PMEA) complex could not be measured due to precipitation [51]
Table 5 Extent of chelate formation according to equilibrium 1 as
expressed by the dimensionless equilibrium constants KI/O (Eqs. 13
and 14) and the percentages of M(PA)cl/O (Eq. 15), based on the
log DM/PA values listed in column 5 of Table 3 for the
M(8,8aPMEA) and M(9,8aPMEA) systems (aqueous solution;
25 C; I=0.1 M, NaNO3)a
PA2 M2+ log DM/PA KI/O % M(PA)cl/O
8,8aPMEA2 Mg2+ 0.15±0.08 0.41±0.26 29±13
Ca2+ 0.06±0.06 0.15±0.16 13±12
Sr2+ 0.08±0.05 0.20±0.14 17±10
Ba2+ 0.13±0.06 0.35±0.19 26±10
Mn2+ 0.15±0.05 0.41±0.16 29±8
Co2+ 0.21±0.07 0.62±0.26 38±10
Ni2+ 0.18±0.06 0.51±0.21 34±9
Cu2+ 0.54±0.08 2.46±0.64 71±5
Zn2+ 0.31±0.11 1.04±0.52 51±12
Cd2+ 0.26±0.09 0.82±0.38 45±11
9,8aPMEA2 Mg2+ 0.14±0.05 0.38±0.16 28±8
Ca2+ 0.09±0.09 0.23±0.26 19±17
Sr2+ 0.12±0.06 0.32±0.18 24±10
Ba2+ 0.16±0.06 0.45±0.20 31±10
Mn2+ 0.18±0.06 0.51±0.21 34±9
Co2+ 0.25±0.07 0.78±0.29 44±9
Ni2+ 0.15±0.09 0.41±0.29 29±15
Cu2+ 0.81±0.07 (5.46±1.04)b (85±2)b
Zn2+ 0.47±0.11 (1.95±0.75)b (66±9)b
Cd2+ 0.28±0.08 0.91±0.35 48±10
aFor the error limits, see footnote (a) of Table 2
bThe parentheses indicate that the stability increase cannot solely
be attributed to equilibrium 1 since in these systems a contribution
from a nucleobase–metal ion interaction also exists [41]. See also
the section ‘‘Cu(9,8aPMEA) and related systems. A four isomer
problem’’
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behave as a PME-R2 ligand, R-CH2CH2-O-CH2-
PO23 , where R does neither participate in metal ion
binding nor aﬀect it in a negative sense, e.g. by steric
inhibition.
Cu(9,8aPMEA) and related systems. A four isomer
problem
The values for D log DCu/PA/PME-R due to the
Cu(9,8aPMEA) and Cu(PMEA) complexes are identical
(Table 4, columns 7 and 8) and in both instances the
increased stability is clearly beyond that attributable to
equilibrium 1 with the ether oxygen interaction and it is
further clear that the additional interaction must be with
the adenine residue. The additional stability increase due
to D log DZn/9,8aPMEA/PME-R for the Zn(9,8aPMEA)
system is clearly also beyond the error limits (Table 4,
column 7). The apparent lack of such an increased sta-
bility for the Zn(PMEA) system (Table 4, column 8) is
no surprise, as the data for this system are based on an
estimation [22, 23, 51], though one should note that,
owing to the relatively large error limits of the values for
the Zn(PMEA) and Zn(9,8aPMEA) systems, the D log
DZn/PA/PME-R values overlap, hence, the properties of the
two systems are probably similar.
For the Ni(9,8aPMEA) and Ni(PMEA) systems
(Table 4, columns 7 and 8) the diﬀering situation is more
complicated to rationalize, since there were no experi-
mental diﬃculties. The D log DNi/PMEA/PME-R value
for the latter system and, hence, a Ni2+–adenine resi-
due interaction, appears as being certain. The diﬀer-
ence between these two systems, 0.15±0.15
[=(0.16±0.10)(0.01±0.11)], seems also to be real,
especially when one takes into account that the given
error is based on 3r; the value for 1r, i.e. 0.15±0.05, still
corresponds to a conﬁdence interval of about 70%.
Hence, it appears that the Ni2+–(N7) interaction is
hampered in the Ni(9,8aPMEA) system, whereas in the
Ni(PMEA) complex exactly this isomer occurs to a
considerable formation degree [41]. It should be noted
that in the Cu2+ and Zn2+ systems the macrochelated
isomer involving N7 is a minority species (see below)
and therefore no diﬀerences in the complexing
properties between PMEA2 and 9,8aPMEA2 show up
for these two metal ions. With Ni2+ this is diﬀerent [41],
as mentioned, but it may be explained with the reduced
basicity of N7 in 9,8aPMEA2 which is due to the eﬀect
of the neighbouring N8 atom.
To complete the picture, the results regarding the
previously established [41, 46] equilibrium scheme 16
need to be summarized shortly. The two isomeric species
M(PA)op and M(PA)cl/O have been discussed and de-
ﬁned above; they correspond to equilibrium 1. The
species M(PA)cl/N7 represents a third isomer and corre-
sponds to the macrochelate seen in equilibrium 2 which
is formed via N7. Finally, the fourth isomer in which not
only a ﬁve-membered chelate involving the phosphate
group and the ether oxygen exists, but in which in
addition also a seven-membered chelate involving the N3
site is formed, is abbreviated as M(PA)cl/O/N3.
The most thoroughly studied system of this kind is
Cu(PMEA) [46]: the formation degrees for any
Cu(PMEA) complex concentrations are 17±3%,
34±10%, 41±12% and 7.7±5.3% (errors 3r) for
Cu(PMEA)op, Cu(PMEA)cl/O, Cu(PMEA)cl/O/N3 and
Cu(PMEA)cl/N7, respectively, showing that the mac-
rochelated isomer involving N7 is a minority species; the
important isomers involve the ether oxygen either in the
form of Cu(PMEA)cl/O or together with N3 as
Cu(PMEA)cl/O/N3. Interestingly, the isomeric distribu-
tion for the Cu(9,8aPMEA) system is within the error
limits (3r) identical with that for the mentioned
Cu(PMEA) system; the values for Cu(9,8PMEA)op,
Cu(9,8aPMEA)cl/O, Cu(9,8aPMEA)cl/O/N3 and
Cu(9,8aPMEA)cl/N7 are 15±3%, 30±10%, 48±11%
and 6.8±4.7%, respectively [41]. This demonstrates how
closely related PMEA2 and 9,8aPMEA2 are in their
metal ion-binding properties, whereas 8,8aPMEA2 is
clearly quite diﬀerent in this respect.
Of further interest is the Zn(9,8aPMEA) system
[41] (see Table 5, the second entry from below), of
which 34±8% exist as the Zn(9,8aPMEA)op isomer,
whereas 32±13%, 24±26% and 10±21% are present
as Zn(9,8aPMEA)cl/O, Zn(9,8aPMEA)cl/O/N3 and
Zn(9,8aPMEA)cl/N7, respectively. Two points need to be
made here: (1) the total amount of chelated species
encompasses 66% (=32+24+10), as already given in
parentheses in Table 5; (2) the large error limits (3r;
conﬁdence limits 99.7%) need to be put into perspective,
i.e. if the error limits are given with one standard deviation
(1r), which corresponds to a conﬁdence limit of
about 70%, the results for Zn(9,8aPMEA)cl/O,
Zn(9,8aPMEA)cl/O/N3 and Zn(9,8aPMEA)cl/N7 are 32±
4%, 24±9% and 10±7%, respectively. Again, the che-
lated isomers involving the ether oxygen are the dominat-
ing ones among the ‘‘closed’’ species and the
macrochelated isomer involving N7 is also in this case a
minority species.
Conclusions
The present results show that the metal ion-binding
properties of 9,8aPMEA2 very closely resemble those of
PMEA2 itself, including the extent of the M2+–ether
M
M2+ + M(PA)op
M(PA)cl/O
M(PA)cl/N7
KI/O
KI/N7
KI/O/N3
KM(PA)op
PA2–
M(PA)cl/O/N3
(16)
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oxygen interaction. It is thus not surprising that
9,8aPMEA also shows antiviral activity [26, 33, 74], al-
though it appears to be somewhat less active but also less
toxic [74]. This contrasts with 8,8aPMEA which shows
no useful biological activity [26, 33] and this despite the
fact that also in its complexes an ether oxygen–metal ion
interaction occurs and that it occurs with biologically
meaningful metal ions like Mg2+, Ca2+ or Mn2+ to the
same extent as with 9,8aPMEA2 or PMEA2 itself.
However, since in the 8-aza isomer the orientation of the
adenine residue is diﬀerent than in PMEA, whereas in
the 9-aza isomer it is identical, this observation regarding
the biological activity is no surprise.
Indeed, owing to this diﬀerent orientation of the
nucleobase moiety, also its binding properties towards
metal ions with an N aﬃnity, like Cu2+, are diﬀerent. In
9-substituted PAs a nucleobase interaction is possible
and with ions like Cu2+ it actually occurs. In contrast,
8,8aPMEA2 behaves in its complexing properties like a
PME-R2 ligand, which oﬀers no binding site in its
residue R. Since in the active site cavity the anchoring
process of a substrate is important [22, 23], and because
this process involves the nucleobase residue and dictates
thus the orientation of the substrate, one may conclude
that at least one of the reasons for the inactivity of
8,8aPMEA is a presumably diﬀerent orientation in the
active site of the polymerase.
In fact, if one considers the structure–function rela-
tionship for nucleotide analogues, one may conclude the
following: if one assumes that 8,8aPMEA and
9,8aPMEA are transported to the cell and also diphos
phorylated like PMEA [75, 76, 77, 78], then it becomes
understandable why 9,8aPMEA shows antiviral activity
and 8,8aPMEA does not [26, 33]. The 9-aza isomer is
structure-wise so similar to PMEA itself (see Fig. 1) that
a facilitated M(Pa) binding (via the ether oxygen) is
possible with 9,8aPMEApp4 and thus also the forma-
tion of the M(Pa)-M(Pb,Pc) binding mode, which is
crucial for the transfer of a nucleotidyl unit in the
polymerase reaction [22, 23]. In contrast, 8,8aPMEA is
anchored with a diﬀerent orientation (due to hydrogen
bonding and stacking [42]) in the active site cavity of the
polymerase, which prevents formation of the indicated
reactive binding mode. To conclude, for biological
activity of an acyclic nucleoside phosphonate derivative
the ether oxygen is compulsory, but it must also be
correctly orientated in space to become eﬀective.
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